Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Article
Pathology
Claud M. Grigg, Chad Livasy, Jiaxian He, Aaron Hartman, Peter E. Clark, Jason Zhu, Derek Raghavan, Earle F. Burgess
Summary: The study evaluated the concordance of HER2 expression in primary urothelial carcinomas and distant metastatic lesions, finding low agreement of HER2-positive status between the two, with loss of HER2 overexpression in some cases. The presence of HER2 ITH impacted the concordance, potentially influencing patient selection for HER2 targeted therapies.
Review
Cell & Tissue Engineering
Hendrik Setia Budi, Firdaus Nuri Ahmad, Harun Achmad, Mohammad Javed Ansari, Maria Vladimirovna Mikhailova, Wanich Suksatan, Supat Chupradit, Navid Shomali, Faroogh Marofi
Summary: Due to the overexpression or amplification of human epidermal growth factor receptor 2 (HER2) with poor prognosis in various human tumors, recent studies have focused on HER2-targeted therapies. Immunotherapy using HER2-specific chimeric antigen receptor (CAR) expressing immune cells has shown great anti-tumor potential and attracted increasing attention.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Oncology
Mangesh A. Thorat, Pauline M. Levey, J. Louise Jones, Sarah E. Pinder, Nigel J. Bundred, Ian S. Fentiman, Jack Cuzick
Summary: Overexpression of HER2 in DCIS is significantly associated with increased risk of in situ recurrence and predicts radiotherapy benefit, with greater reductions in in situ recurrences in HER2-positive DCIS.
CLINICAL CANCER RESEARCH
(2021)
Article
Chemistry, Analytical
Junjun Luo, Dong Liang, Xiaoqing Li, Shuping Liu, Lei Deng, Fanghui Ma, Zaoxia Wang, Minghui Yang, Xiang Chen
Summary: A sensitive photoelectrochemical (PEC) sensor was prepared using hexagonal carbon nitride tubes (HCNT) as the photoactive material, and magnetic Fe3O4 nanospheres and Co3O4 nanoparticles were employed for signal amplification. The sensor showed a wide linear response range and a low detection limit for HER2 detection in human serum samples.
Review
Multidisciplinary Sciences
Boris Itkin, Agustin Garcia, Samanta Straminsky, Eduardo Daniel Adelchanow, Matias Pereyra, Gabriela Acosta Haab, Ariel Bardach
Summary: The reported rates of HER2 positivity in cervical cancer vary widely and are influenced by methodological issues. Results suggest that a small percentage of CC is HER2-positive, with higher prevalence in studies compliant with ASCO/CAP guidelines. High heterogeneity was a main limitation of the study.
Review
Oncology
Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
Summary: HR+/HER2+ metastatic breast cancer is a unique subtype of breast cancer. Combination regimens and endocrine therapy can provide long-term disease control, but accurately identifying the subset of patients who can benefit from de-chemotherapy treatment strategy is challenging.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Tenley R. Klc, Sharon Wu, Annelise M. Wilhite, Nathaniel L. Jones, Matthew A. Powell, Alex Olawaiye, Eugenia Girda, Jubilee Brown, Allison Puechl, Rouba Ali-Fehmi, Ira S. Winer, Thomas J. Herzog, W. Michael Korn, Britt K. Erickson
Summary: This study assessed the concordance of HER2 positivity and identified downstream mutations that may affect response to HER2 directed therapy in uterine serous carcinoma. The results showed high concordance between CISH and IHC for HER2 positivity, with NGS having the lowest positivity rate.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Weiyuan Huang, Qihao Zhang, Gang Wu, Pian Pian Chen, Jiao Li, Kelly McCabe Gillen, Pascal Spincemaille, Gloria C. Chiang, Ajay Gupta, Yi Wang, Feng Chen
Summary: The study demonstrates that DCE-MRI can detect the expression levels of HIF-1α, EGFR, and Ki-67 in nasopharyngeal carcinoma (NPC) patients by quantitatively measuring tumor blood flow, vascularity, and permeability, with |u| and K-trans serving as noninvasive imaging markers for detecting hypoxia and proliferation.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Pathology
Luisa Vera Muscatello, Enrico Di Oto, Miriam Dignazzi, William J. Murphy, Ilaria Porcellato, Raffaella De Maria, Terje Raudsepp, Maria Pia Foschini, Monica Sforna, Cinzia Benazzi, Barbara Brunetti
Summary: HER2 is found to be overexpressed and amplified in a subset of feline pulmonary carcinomas, with a significant correlation between protein overexpression and gene amplification. Further studies with additional cases are needed to confirm HER2 as a potential target for innovative treatments.
VETERINARY PATHOLOGY
(2021)
Article
Oncology
Hai Luo, Lingzhi Cui, Kexin Shen, Ruiqi Li, Zeming Wang, Zhongshi Xie
Summary: The study revealed a significant correlation between HER2 overexpression and various clinicopathological parameters in colorectal cancer patients, leading to poorer prognosis. Deficiencies in MLH1, MSH-2, MSH-6, or PMS-2 were associated with tumor location and may serve as additional markers in CRC risk assessments.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Multidisciplinary Sciences
Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Ki-Tae Hwang, Young Jin Suh, Chan-Heun Park, Young Joo Lee, Jee Ye Kim, Jin Hyang Jung, Seeyeong Kim, Junwon Min
Summary: In patients with DCIS, the ER+/PR+ subtype showed better prognoses with tamoxifen therapy. PR status is a favorable prognostic factor in patients with DCIS who received tamoxifen therapy.
Article
Veterinary Sciences
L. Muscatello, F. Gobbo, E. Di Oto, G. Sarli, R. De Maria, A. De Leo, G. Tallini, B. Brunetti
Summary: HER2 amplification was found in a subgroup of canine mammary carcinomas, with the HER2 gene copy number correlated with HER2 protein overexpression but not with tumor behavior. Additionally, a possible translocation of HER2/CRYBA1 was discovered. This study highlights the potential for different amplification patterns in studying HER2 in canine mammary tumors.
VETERINARY SCIENCES
(2022)
Article
Surgery
Sol Ji Ahn, Chang Ik Yoon, Pill Sun Paik, Tae-Kyung Yoo, Namsun Park, Eun Sook Lee, Jung Eun Choi, Joon Jeong, Hyun Jo Youn, Woo-Chan Park
Summary: This study aimed to identify the mortality risk in patients with HER2-positive DCIS. The results indicated that older age, higher BMI, mastectomy, and lack of endocrine therapy were significant factors associated with mortality risk. Further validation and analysis using large databases are needed for this finding.
ANNALS OF SURGICAL TREATMENT AND RESEARCH
(2021)
Article
Oncology
Laura Sala, Stefano Bonomi, Alessandra Fabbri, Chiara Maura Ciniselli, Annalisa Bardelli, Paolo Verderio, Giancarlo Pruneri, Umberto Cortinovis
Summary: This study investigated the use of the PEAK PlasmaBlade and acellular dermal matrix Veritas in implant-based breast reconstruction in the setting of radiotherapy. The results showed that this approach could lead to lower complication rates and higher levels of patient and surgeon satisfaction.
Article
Oncology
C. Sessa, J. Balmana, S. L. Bober, M. J. Cardoso, N. Colombo, G. Curigliano, S. M. Domchek, D. G. Evans, D. Fischerova, N. Harbeck, C. Kuhl, B. Lemley, E. Levy-Lahad, M. Lambertini, J. A. Ledermann, S. Loibl, K. -A. Phillips, S. Paluch-Shimon
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
G. Spitaleri, P. Trillo Aliaga, C. Catania, E. Del Signore, I. Attili, C. Santoro, F. Giugliano, P. P. M. Berton Giachetti, G. . Curigliano, A. Passaro, F. de Marinis
Summary: This prospective trial examined the safety of COVID-19 vaccines in patients with thoracic cancer receiving anticancer treatments. The results showed no safety concerns and a low rate of vaccine-related adverse events. The study supports prioritizing vaccination for lung cancer patients undergoing active treatment.
CLINICAL LUNG CANCER
(2023)
Review
Oncology
Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano
Summary: Phosphoinositide 3-kinases (PI3Ks) play a crucial role in tumorigenesis, particularly the p110 alpha subunit (PIK3CA) with activating mutations found in various tumors. Current PI3K inhibitors have limited efficacy due to on-target toxicity, inhibiting both wild-type and mutant PI3Ks. However, the development of mutant and isoform selective PIK3CA inhibitors has surged interest in targeting PIK3CA in solid tumors. This review summarizes the understanding of PI3K alterations, treatment strategies, and emerging resistance mechanisms and the role of mutant selective PIK3CA inhibitors.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Chiara Corti, Federica Giugliano, Eleonora Nicolo, Paolo Tarantino, Carmen Criscitiello, Giuseppe Curigliano
Summary: Breast cancer is divided into three main groups: hormone receptor-positive HER2-negative, HER2-positive, and triple-negative BC. Technological breakthroughs have allowed for the development of antibody-drug conjugates (ADCs) as a treatment option. Even with low HER2 receptor expression, the use of T-DXd may provide clinical benefit for HER2-positive breast cancer. In HR-negative HER2-low subtype, the use of T-DXd is justified despite limited evidence, considering the poor prognosis of TNBC.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Pamela Trillo, Jose Sandoval, Dario Trapani, Eleonora Nicolo, Paola Zagami, Federica Giugliano, Paolo Tarantino, Grazia Vivanet, Liliana Ascione, Alex Friedlaender, Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano
Summary: The study retrospectively analyzed data of patients with recurrent invasive lobular carcinoma (ILC) and found discordance in the expression of ER, PgR, and HER2 between primary tumors and metastases. These findings suggest that phenotypic switch during metastasis may have implications for treatment decisions and prognosis in patients with ILC.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Luca Boscolo Bielo, Dario Trapani, Giuseppe Curigliano
Summary: Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer with unfavorable outcomes, traditionally had limited systemic treatment options. However, novel drugs have been approved and are causing economic challenges due to their high prices.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Review
Oncology
Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele
Summary: This is a summary of an article about a study called P-REALITY X, which found that patients with metastatic HR+/HER2- breast cancer treated with palbociclib plus an AI lived longer than those treated with an AI only in routine clinical practice. These results support the use of palbociclib plus an AI as the standard first-line treatment for this type of breast cancer.
Review
Genetics & Heredity
Mariia Ivanova, Francesca Maria Porta, Federica Giugliano, Chiara Frascarelli, Elham Sajjadi, Konstantinos Venetis, Giulia Cursano, Giovanni Mazzarol, Elena Guerini-Rocco, Giuseppe Curigliano, Carmen Criscitiello, Nicola Fusco
Summary: Breast cancer is a widely prevalent and deadly malignancy, with brain metastases being a significant contributor to mortality. The formation, progression, and colonization of primary breast tumors and subsequent brain metastases involve diverse molecular pathways, which complicates their clinical management. Despite advancements in primary breast cancer treatments, the prognosis for patients with brain metastases remains poor. This review aims to highlight the biological mechanisms of breast cancer brain metastases and discuss available and emerging treatment strategies for managing this complex disease.
Review
Oncology
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Giuseppe Curigliano
Summary: HER2-positive metastatic breast cancer is a subtype of breast cancer with aggressive behavior and sensitivity to HER2-targeted agents. Antibody-drug conjugates (ADCs), such as T-DM1 and T-DXd, have shown improved clinical outcomes in this subtype. However, resistance to these ADCs still occurs, highlighting the need for understanding the underlying mechanisms.
Review
Oncology
Federica Giugliano, Ambra Carnevale Schianca, Chiara Corti, Mariia Ivanova, Nadia Bianco, Silvia Dellapasqua, Carmen Criscitiello, Nicola Fusco, Giuseppe Curigliano, Elisabetta Munzone
Summary: Breast cancer is common and approximately 15% are HER2-positive. HER2 protein expression can be heterogeneous, affecting treatment choices. Novel pharmacological agents, such as antibody-drug conjugates, may help overcome this issue.
Review
Cell Biology
Gabriele Antonarelli, Valentina Pieri, Francesca Maria Porta, Nicola Fusco, Gaetano Finocchiaro, Giuseppe Curigliano, Carmen Criscitiello
Summary: Various tumors rely on post-translational modifications to promote invasiveness, angiogenesis, and reprogram cellular energetics. Fucosylation, a type of glycosylation, has been linked to immune and hormonal functions as well as tumor development. In breast cancer, fucosylation of the glycan core is associated with poor prognosis and increased metastatic potential. Pre-clinical studies have investigated the molecular mechanisms of core-fucosylation in breast cancer models and its potential as a biomarker for predicting cancer outcomes.
Article
Oncology
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Summary: In 428 patients with HR+/HER2- advanced breast cancer, HER2-low status was found to be independently associated with worse progression-free survival (PFS) and overall survival (OS) compared to HER2-0 status. These findings suggest that HER2-low status could serve as a new prognostic biomarker in this clinical setting.
Article
Oncology
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Summary: This study evaluates whether Oncotype DX improves confidence and agreement among oncologists in adjuvant chemotherapy recommendations for ER+/HER2- early-stage breast cancers. The study found that using Oncotype DX significantly reduces discordance and uncertainty among oncologists, and improves agreement in adjuvant chemotherapy recommendations for patients.
Article
Oncology
Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frederique Penault-Llorca, Aleix Prat
Summary: Breast cancer multigene signatures (BCMS) have changed the management of early-stage breast cancer (eBC) by providing prognostic information and helping select patients for adjuvant chemotherapy. However, there is limited knowledge on the current usage and perceived utility of BCMS in clinical practice. A two-round Delphi survey involving 133 breast cancer experts from 11 European countries revealed that BCMS are widely used to assess risk of recurrence and select patients for adjuvant chemotherapy, but consensus is lacking regarding their utility in selecting specific chemotherapy types. There are also discrepancies between recommended usage and actual usage, with some profiles lacking supporting evidence. The study suggests the need for physician education initiatives to ensure proper use and interpretation of BCMS, ultimately improving management of eBC patients.
